Want to see PLSE full AI Analyst Report?
PLSE Stock Chart & Stats
$23.40
-$0.27(-1.46%)
At close: 4:00 PM EST
$23.40
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $31.00
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$1.82B
Enterprise Value$1.70B
Total Cash (Recent Filing)$68.32M
Total Debt (Recent Filing)$7.16M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 12, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding69,209,710
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-0.73
Price to Book (P/B)11.47
Price to Sales (P/S)2643.82
P/FCF Ratio-17.00
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue2.26K
Enterprise Value/Gross Profit-2.49K
Enterprise Value/Ebitda-22.95
Forecast
1Y Price Target
$32.00Price Target Upside36.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$2.63M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy & SafetyRobust clinical outcomes from the 177‑patient European feasibility study materially de‑risk the core technology. Durable efficacy and low SAE rates support regulatory approvals, bolster physician confidence, and create a lasting clinical credibility advantage that aids adoption and reimbursement conversations.
Regulatory & Trial AccelerationInitiation and acceleration of the pivotal U.S. IDE, plus a Bayesian design and planned CE submission, shorten the path to market. Reduced follow‑up and faster enrollment materially lower regulatory timing risk, improving the company's ability to commercialize and generate recurring revenues sooner.
Financing Flexibility & Modest LeverageExisting cash, a large shelf registration and ATM availability provide optionality to fund pivotal trials and operations. Coupled with modest debt levels, this structural financing flexibility reduces near‑term insolvency risk and gives the company time to execute clinical and commercial milestones.
Bears Say
High Cash BurnSustained negative operating and free cash flow indicate substantial ongoing burn. This creates persistent financing dependency, elevates dilution risk, and imposes execution pressure to either accelerate commercial adoption or continually access capital to fund pivotal trials and operations over the coming months.
Deep Losses & Negative MarginsVery large TTM net losses and negative gross profit show the cost base far exceeds revenue. Persistently negative margins erode equity, limit reinvestment capacity, and mean profitability depends on successful scaling of device and consumable sales alongside strict cost control.
Commercial ImmaturityMinimal product revenue and near‑break‑even cost of goods indicate the business has yet to establish recurring consumable economics. Commercial immaturity prolongs the timeline to sustainable revenue and increases execution risk that clinical success will not translate quickly into durable market uptake.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $31.00 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $1.82B.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on May 04, 2026. The company reported -$0.238 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.032.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.29.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 69,209,710 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.238 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.841%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$32.00 (36.75% Upside)
$32.00 (36.75% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 31.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $13.3M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-86.67%
Trailing 12-Months
Asset Growth
-38.81%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
PLSE Stock 12 Month Forecast
Average Price Target
$32.00
▲(36.75% Upside)
Technical Analysis
Ownership Overview
73.02% Insiders
2.26% Mutual Funds
1.81% Other Institutional Investors
19.97% Public Companies and
Individual Investors